1. Home
  2. AEYE vs QTTB Comparison

AEYE vs QTTB Comparison

Compare AEYE & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

HOLD

Current Price

$7.16

Market Cap

74.9M

Sector

Technology

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$5.54

Market Cap

80.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEYE
QTTB
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.9M
80.0M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
AEYE
QTTB
Price
$7.16
$5.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$14.63
$13.00
AVG Volume (30 Days)
174.1K
306.7K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
30.56
136.78
EPS
N/A
2.42
Revenue
$40,311,000.00
$53,737,000.00
Revenue This Year
$11.12
N/A
Revenue Next Year
$11.45
N/A
P/E Ratio
N/A
$2.37
Revenue Growth
14.52
N/A
52 Week Low
$5.31
$1.40
52 Week High
$16.39
$8.05

Technical Indicators

Market Signals
Indicator
AEYE
QTTB
Relative Strength Index (RSI) 58.03 45.44
Support Level $6.35 $5.51
Resistance Level $7.42 $7.69
Average True Range (ATR) 0.38 0.64
MACD 0.06 -0.08
Stochastic Oscillator 81.09 30.49

Price Performance

Historical Comparison
AEYE
QTTB

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Share on Social Networks: